A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Beijing is emerging as a global hub for pharmaceutical innovation as eight international pharmaceutical companies plan to establish research and development centers in the city.

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep ...